Epigral’s In-House R&D Unit

Corporate Update

Epigral’s In-House R&D Unit Receives Recognition From India’s Ministry Of Science & Technology

The Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology, Government of India has accorded recognition to Epigral Limited’s in-house R&D unit at Changodar, Ahmedabad, Gujarat.

This registration will entitle the inhouse R&D unit to avail customs duty exemption on the import/purchase of equipment, instruments, spares thereof, consumables, etc, used for research and development activities during the period of recognition i.e. from February 15, 2024 to March 31, 2026.

The R&D Centre is built over 14,374 sqmt and has the latest, state-of-the-art technologies installed that will enable Epigral to catalyse identification of specialty chemical molecules for later introduction in India. The company has consciously strived towards creating a key differentiator for itself by graduating from being a chemical manufacturer to developing research-driven products, in-house.

The centre has been developed with an initial investment of Rs 30 crore and the company will further invest to enhance its capability as it proceeds further.

Through research and development, the company intends to introduce new molecules indigenous to India and address domestic and global custom manufacturing requirements. This centre will help discovering new molecules within the Chlorotoluene ecosystem and further establish advanced speciality intermediates.